Histone Deacetylase 1 Pipeline Review, H2 2019
Summary
Histone Deacetylase 1 HDAC1 or EC 3.5.1.98 pipeline Target constitutes close to 33 molecules. Out of which approximately 25 molecules are developed by companies and remaining by the universities/institutes. The latest report Histone Deacetylase 1 Pipeline Review, H2 2019, outlays comprehensive information on the Histone Deacetylase 1 HDAC1 or EC 3.5.1.98 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.
Histone Deacetylase 1 HDAC1 or EC 3.5.1.98 Histone deacetylase 1 is an enzyme encoded by the HDAC1 gene. The protein encoded by this gene belongs to the histone deacetylase family and is a component of the histone deacetylase complex. It also interacts with retinoblastoma tumorsuppressor protein and this complex is a key element in the control of cell proliferation and differentiation. Together with metastasisassociated protein2 MTA2, it deacetylates p53 and modulates its effect on cell growth and apoptosis. It plays an important role in transcriptional regulation, cell cycle progression and developmental events. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 4, 5, 14 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 7 and 1 molecules, respectively.
Report covers products from therapy areas Oncology, Central Nervous System, Hematological Disorders, Genetic Disorders, Gastrointestinal, Immunology, Infectious Disease and Musculoskeletal Disorders which include indications Breast Cancer, Acute Lymphocytic Leukemia ALL, Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Follicular Lymphoma, Diffuse Large BCell Lymphoma, Hodgkin Lymphoma BCell Hodgkin Lymphoma, Lymphoma, Melanoma, Mycosis Fungoides, NonSmall Cell Lung Cancer, Adenoid Cystic Carcinoma ACC, BCell NonHodgkin Lymphoma, Burkitt Lymphoma, Colorectal Cancer, Cutaneous TCell Lymphoma, Epithelial Ovarian Cancer, Essential Thrombocythemia, Glioblastoma Multiforme GBM, Lung Cancer, Mantle Cell Lymphoma, Marginal Zone Bcell Lymphoma, Metastatic Melanoma, Multiple Myeloma Kahler Disease, Myelodysplastic Syndrome, Neuroblastoma, Pancreatic Cancer, Parkinson's Disease, PostPolycythemia Vera Myelofibrosis PPVMF, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Squamous Cell Carcinoma, Thalassemia, TripleNegative Breast Cancer TNBC, Adenocarcinoma Of The Gastroesophageal Junction, Alzheimer's Disease, Anaplastic Large Cell Lymphoma ALCL, Angioimmunoblastic TCell Lymphoma AITL/Immunoblastic Lymphadenopathy, Basal Cell Carcinoma Basal Cell Epithelioma, Becker Muscular Dystrophy, Bile Duct Cancer Cholangiocarcinoma, Blood Cancer, Bone Disorders, Central Nervous System CNS Tumor, CharcotMarieTooth Disease Type II, Chronic Lymphocytic Leukemia CLL, CNS Lymphoma, Cognitive Disorders, Colon Cancer, Depression, Duchenne Muscular Dystrophy, Endometrial Cancer, Fallopian Tube Cancer, Gallbladder Cancer, Gastrointestinal Tract Cancer, Gliosarcoma, Hematological Tumor, Hemoglobinopathies, HighGrade Glioma, Human Immunodeficiency Virus HIV Infections AIDS, Human Papillomavirus HPV Associated Cancer, Liver Cancer, Liver Fibrosis, Lung Adenocarcinoma, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Renal Cell Carcinoma, Metastatic Uveal Melanoma, Multiple Sclerosis, Muscle Invasive Bladder Cancer MIBC, Myelofibrosis, Natural Killer Cell Lymphomas, Neuroendocrine Cancer, NonHodgkin Lymphoma, NUT Midline Carcinoma NMC or Nuclear Protein in Testis Midline Carcinoma, Pediatric Diffuse Intrinsic Pontine Glioma, Peripheral TCell Lymphomas PTCL, Peritoneal Cancer, Polycythemia Vera, PostEssential Thrombocythemia Myelofibrosis PostET MF, Prostate Cancer, Recurrent Medulloblastoma, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia CLL, Relapsed Chronic Lymphocytic Leukemia CLL, Renal Cell Carcinoma, Sezary Syndrome, Sickle Cell Disease, Skin Cancer, Solid Tumor and Systemic Lupus Erythematosus.
Furthermore, this report also reviews key players involved in Histone Deacetylase 1 HDAC1 or EC 3.5.1.98 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Scope
The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 1 HDAC1 or EC 3.5.1.98
The report reviews Histone Deacetylase 1 HDAC1 or EC 3.5.1.98 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Histone Deacetylase 1 HDAC1 or EC 3.5.1.98 targeted therapeutics and enlists all their major and minor projects
The report assesses Histone Deacetylase 1 HDAC1 or EC 3.5.1.98 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Histone Deacetylase 1 HDAC1 or EC 3.5.1.98 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Histone Deacetylase 1 HDAC1 or EC 3.5.1.98
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Histone Deacetylase 1 HDAC1 or EC 3.5.1.98 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope